A Study to Evaluate the Efficacy and Safety of MK-5172 in Combination with Peginterferon alfa 2b and Ribavirin in Cirrhotic and Non-cirrhotic Patients with Hepatitis C Virus (HCV) genotype 1 Infection

Trial Profile

A Study to Evaluate the Efficacy and Safety of MK-5172 in Combination with Peginterferon alfa 2b and Ribavirin in Cirrhotic and Non-cirrhotic Patients with Hepatitis C Virus (HCV) genotype 1 Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2015

At a glance

  • Drugs Grazoprevir (Primary) ; Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top